- Ticker
- ABSI
- Price
- 3.35
- Stock movement down
- -0.04 (-1.18%)
- Company name
- Absci Corp
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 309.52M
- Ent value
- 248.64M
- Price/Sales
- 91.71
- Price/Book
- 1.06
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -54.61%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2023-02-03
DIVIDENDS
ABSI does not pay dividends
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 91.71 |
| Price to Book | 1.06 |
| EV to Sales | 73.67 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 92.39M |
| EPS (TTM) | -1.21 |
| FCF per share (TTM) | -1.14 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 3.38M |
| Gross profit (TTM) | -3.28M |
| Operating income (TTM) | -111.91M |
| Net income (TTM) | -110.60M |
| EPS (TTM) | -1.21 |
| EPS (1y forward) | -1.06 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -97.16% |
| Operating margin (TTM) | -3315.94% |
| Profit margin (TTM) | -3277.01% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 107.32M |
| Net receivables | 210.00K |
| Total current assets | 201.38M |
| Goodwill | 21.34M |
| Intangible assets | 52.47M |
| Property, plant and equipment | 0.00 |
| Total assets | 339.39M |
| Accounts payable | 1.86M |
| Short/Current long term debt | 22.14M |
| Total current liabilities | 30.03M |
| Total liabilities | 46.45M |
| Shareholder's equity | 292.94M |
| Net tangible assets | 240.48M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -79.85M |
| Capital expenditures (TTM) | 23.93M |
| Free cash flow (TTM) | -103.78M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -37.75% |
| Return on Assets | -32.59% |
| Return on Invested Capital | -36.15% |
| Cash Return on Invested Capital | -33.92% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.40 |
| Daily high | 3.63 |
| Daily low | 3.31 |
| Daily Volume | 533K |
| All-time high | 30.29 |
| 1y analyst estimate | 12.00 |
| Beta | - |
| EPS (TTM) | -1.21 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 21 Mar 2023 |
Downside potential
Loading...
Downside potential data
| ABSI | S&P500 | |
| Current price drop from All-time high | -88.94% | -13.68% |
| Highest price drop | -93.40% | -56.47% |
| Date of highest drop | 27 Dec 2022 | 9 Mar 2009 |
| Avg drop from high | -74.60% | -11.49% |
| Avg time to new high | 65 days | 13 days |
| Max time to new high | 380 days | 1805 days |
COMPANY DETAILS
Marketcap
309.52M
Marketcap category
Small-cap
Description
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Employees
211
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
In this article, we will discuss the 10 penny stocks that will make you a millionaire. If you want to explore similar stocks, you can also take a look at 5 Penny Stocks That Will Make You A Millionair...
January 10, 2023
The discovery could reduce the time it takes to get new drug candidates to clinic to 18-24 months from six years.
January 10, 2023
This breakthrough unlocks the potential to accelerate time to clinic by over 50% and increase probability of success in the clinic Creating antibodies in silico with generative AI represents a major i...
January 10, 2023
VANCOUVER, Wash. and NEW YORK, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...
January 8, 2023
It's not a secret that every investor will make bad investments, from time to time. But it should be a priority to...
December 29, 2022
VANCOUVER, Wash. and NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...
November 23, 2022
VANCOUVER, Wash. and NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...
November 17, 2022
The company continued to lose money but its CEO says it has enough cash to sustain it through the end of 2025.
November 9, 2022
Absci Corporation (ABSI) delivered earnings and revenue surprises of -11.11% and 32.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
November 9, 2022
Milestone achievement and progress continues in previously announced Merck collaboration Further strengthened executive leadership and Board of Directors VANCOUVER, Wash. and NEW YORK, Nov. 09, 2022 (...
November 9, 2022
Next page